Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and ...

The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from ...

The SNIPRx-surf platform is designed to detect cell surface targets in tumours or cancer models, utilising gene expression, ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug ...